Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 3/20 | 0.45 |
| ▸ | EGFR | P00533 | 2/20 | 0.45 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.41 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.40 |
| ▸ | AKT1 | P31749 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.38 |
| ▸ | CHUK | O15111 | 1/20 | 0.38 |
| ▸ | CDC7 | O00311 | 1/20 | 0.38 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27075654 | 0.85 | MAPK1 (0.48) | IGF1REGFRROCK2KMT2AGRM4 | |
| SCHEMBL27075640 | 0.82 | IDO1 (0.50) | EGFRROCK2EIF2AK2CHUK | |
| SCHEMBL27171325 | 0.73 | KMT2A (0.44) | IGF1REGFRROCK2KMT2AGRM4 | |
| SCHEMBL31356299 | 0.70 | KMT2A (0.51) | IGF1REGFRROCK2KMT2AGRM4 | |
| SCHEMBL27075634 | 0.69 | LTA4H (0.44) | RAB9AEIF2AK2NPC1MAPK1CLK4 | |
| SCHEMBL31485518 | 0.69 | KMT2A (0.47) | IGF1REGFRROCK2KMT2AGRM4 | |
| SCHEMBL27207634 | 0.69 | CDC7 (0.38) | IGF1REGFRGRM4RPS6KB1AKT1 | |
| SCHEMBL27075653 | 0.69 | IDO1 (0.53) | EGFRROCK2CHUK | |
| SCHEMBL31193286 | 0.67 | CDK9 (0.55) | — | |
| SCHEMBL27171379 | 0.67 | KMT2A (0.47) | IGF1REGFRKMT2AGRM4RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11891390-B1 | 3-substituted amino-2-arylpyrrolo[2,3-c]pyridines as CK2 inhibitors | King Faisal University (SA) | 2024-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11891390-B1 | 3-substituted amino-2-arylpyrrolo[2,3-c]pyridines as CK2 inhibitors | CSNK2A3, CSNK2A2, CSNK2A1 | IGF1R 2065/4885EGFR 400/4885ROCK2 2951/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.